GENERAL APPROACHES FOR DOSE ADJUSTMENT IN RENAL DISEASE Renal insufficiency can markedly alter one or more of the pharmacokinetic parameters of a drug including oral bioavailability‚ volume of distribution‚ drug binding to plasma proteins‚ and most importantly the rates of metabolism and excretion‚ i.e.‚ drug clearance.. To minimize drug toxicity and maximize therapeutic benefits‚ it is often necessary to adjust drug dosage in proportion to the degree of renal insufficiency. A drug will most
Premium Pharmacology Nephrology Renal failure
Münchausen Syndrome and Münchausen Syndrome By Proxy Münchausen Syndrome There are many syndromes in people’s lives. All of the sydromes have been effecting people’s health negatively in people lives since the existence of human being. One of the most interesting syndrome is Munchausen Syndrome. It is related to unreal illness. In other words‚ Some people who has münchausen syndrome can cause an illness own their own. Therefore‚ they are actually clever and have medical information. Due to their
Premium Medicine
September 28‚ 2007 Notification No.0928010 Attention to: Commissioner of Prefectural Health Supervising Department From Director of Evaluation and Licensing Division‚ Pharmaceutical and Food Safety Bureau Ministry of Health‚ Labour and Welfare Basic principles on Global Clinical Trials* Up to the present according to “Ethnic Factors in the Acceptability of Foreign Clinical Data” based on ICH-E5 guideline (Notification. No. 762‚ Director of Evaluation and Licensing Division‚ Pharmaceutical
Premium Clinical trial Pharmaceutical industry Pharmacology
GLIPIZIDE EXTENDED RELEASE TABLETS FOR ORAL USE DESCRIPTION Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The Chemical Abstracts name of glipizide is 1-cyclohexyl-3-[[p-[2-(5methylpyrazinecarboxamido)ethyl] phenyl]sulfonyl]urea. The molecular formula is C21H27N5O4S; the molecular weight is 445.55; the structural formula is shown below: N HC 3 N CONHCH2CH2 SO NHCONH 2 Glipizide is a whitish‚ odorless powder with a pKa of 5.9. It is insoluble in water and
Premium Diabetes mellitus Insulin
caution Children Use with caution Mechanism Of Action Theophylline-7-acetate ha bronchodilator effect due to inhibition of the intracellular phosphodiesterases‚ followed by increase in cyclic AMP level wh....More details..... PharmacoKinetics Absorption: Absorbed after oral administration Distribution: Widely distributed in the body Metabolism: Metabolised in the liver Excretion: Excrete....More details..... OnsetOfAction 1 to 2 hours....More details..... AdverseEffect
Premium Pharmacology
(2004). Milrinone for the treatment of cardiac dysfunction in neonates (Protocol) (Publication no. 10.1002/14651858.CD004952.). from John Wiley & Sons‚ Ltd: McCance‚ K Ramamoorthy‚ C.‚ Anderson‚ G. D.‚ Williams‚ G. D.‚ & Lynn‚ A. M. (1998). Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery. Anesthesia & Analgesia‚ 86(2)‚ 283-289. Ravishankar‚ C.‚ Tabbutt‚ S.‚ & Wernovsky‚ G. (2003). Critical care in cardiovascular medicine. Current opinion in Pediatrics
Premium Randomized controlled trial Cardiology Clinical trial
International Conference on Harmonisation International Committee of Medical Journal Editors Indian National Rupee intravenous Market Authorization New Drug Application National Regulatory Authority Optical Character Recognition Pharmacodynamics Pharmacokinetics per oral Quality Overall Summary World Health Organization Page 2 of 110 GUIDELINES ON COMMON TECHNICAL DOCUMENT (CTD) 28.10.2010 2 TABLE OF CONTENTS 1 2 3 4 5 ABBREVIATIONS .....................................................
Premium Pharmacology Clinical trial Drug development
3. The observed and WB-PBPK model simulated mean plasma concentration-time profiles of caspofungin in healthy adults after intravenous doses of 20 mg‚ 40 mg‚ 70 mg and 100 mg are graphically presented in Figure 1. The predicted and observed pharmacokinetic parameters with the prediction accuracy are summarized
Premium Dose Simulation Reference dose
Diuretics Hypertension‚ Congestive Heart Failure ‚ Diabetes‚ Cirrhosis and Renal Failure Objectives I. Review renal structure and function II. Neurohumoral regulation of water (ECF) & electrolyte balance III. Pharmacotherapy that acts at the kidney A. Loop diuretics B. Thiazide diuretics C. Carbonic Anhydrase Inhibitors D. K+- sparing diuretics E. Osmotic diuretics F. Others IV. Therapeutic uses I. Structure/Function Germann and Stanfield Fig. 19.2 The Nephron: Tubular Component
Premium Nephron Kidney
VIAGRA® (sildenafil citrate) Tablets DESCRIPTION VIAGRA®‚ an oral therapy for erectile dysfunction‚ is the citrate salt of sildenafil‚ a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6‚7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4‚3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate and has the following structural formula: O C H 3C H 2 O CH3 N HN N
Premium Blood pressure Erectile dysfunction